PRKDC and head and neck squamous cell carcinoma: To test this hypothesis, we investigated the in vitro and in vivo effects of the DNA-PK inhibitor NU7441 and the PARP inhibitor olaparib with irradiation in HPV-negative HNSCC cell lines.